Navigation Links
Xencor Reports Second Quarter 2014 Financial Results
Date:7/31/2014

ergic subjects, with preliminary data anticipated by the end of 2014. The trial will evaluate safety, pharmacokinetics and immunogenicity of a single ascending dose of XmAb7195 in a total of 64 subjects. The study will also evaluate the effect on free and total IgE levels, in addition to immune cell biomarkers, in healthy subjects and in allergic subjects with elevated levels of IgE.

XmAb5871

  • Xencor remains on track to report top-line data from the Phase 2a trial of XmAb5871 in patients with moderate-to-severe rheumatoid arthritis in the second half of 2014.
  • Bispecific Antibody Program

  • Xencor has produced preclinical candidates targeting i) CD3 and CD38 for use in multiple myeloma, ii) CD3 and CD123 for use in acute myeloid leukemia, and iii) CD3 and CD20 for use in B-cell cancers. Xencor is in the final process to select one of its lead bispecific antibodies for Investigational New Drug (IND)-enabling development.
  • Preclinical pharmacology studies and manufacturing cell line development are underway for these three bispecific antibody candidates.
  • Executive Appointments

  • In July 2014, Xencor announced the appointment of Kurt Gustafson to its board of directors and the promotion of John Desjarlais, Ph.D., to senior vice president of research and chief scientific officer.
  • Second Quarter and Six Months Ended June 30, 2014 Financial ResultsRevenues for the second quarter ended June 30, 2014 were $0.8 million, compared to $3.9 million in the same period of 2013. Revenues for the six month period ended June 30, 2014 were $3.0 million, compared to $5.3 million for the same period in 2013. The reduction in revenue for the three and six months ended June 30, 2014 compared to the same periods in 2013 relates primarily to the $3.0 million in milestone revenue received under the Company's Morphosys collaboration in the second quarter of 2013. Revenues are earned from tech
    '/>"/>

    SOURCE Xencor Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Xencor to Host Second Quarter 2014 Financial Results Webcast and Conference Call
    2. Xencor Appoints Kurt Gustafson to Board of Directors; Promotes John Desjarlais to Chief Scientific Officer
    3. Xencor, Inc. Announces Closing of Initial Public Offering
    4. Pharmacyclics Reports Second Quarter 2014 Results
    5. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
    6. Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015
    7. HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013
    8. Endo Reports Second Quarter Financial Results
    9. Columbia Laboratories Reports Second Quarter 2014 Financial Results
    10. Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results
    11. Hospira Reports Second-Quarter 2014 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/19/2014)... BURLINGTON, Mass. , Dec. 18, 2014  Decision ... the United States will increase ... Growth will be primarily driven by expansion in the ... direct energy devices will be increasingly adopted due to ... launched. Other key findings from Decision Resources ...
    (Date:12/19/2014)... KANSAS CITY, Kan. , Dec. 18, 2014 ... PETX ), a biopharmaceutical company focused on ... for companion animals, today announced positive results from ... company,s innovative drug for treating pain in dogs ... demonstrated improvements in pain assessment scores that were ...
    (Date:12/17/2014)... -- Revenue and earnings above the previous year ... In the past 2013/14 fiscal year (ended 30 ... EUR 4.287 billion (last year: EUR 4.190 billion) despite unfavorable ... 360 million. "Overall, 2013/14 was a successful fiscal year for ... and CEO of Carl Zeiss AG. "Thanks to our broad ...
    Breaking Medicine Technology:U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2
    (Date:12/19/2014)... Diet Doc strives to continue to ... weight loss by combining scientific fast weight ... the company understand that remaining committed to a diet ... carbohydrates and sugars from the diet can cause patients ... weight loss goals. , For this reason, Diet ...
    (Date:12/19/2014)... December 19, 2014 B. E. Smith, ... healthcare providers, has been retained to lead a national ... Medical Center in Estes Park, Colo. The top executive ... has recently placed more than 900 healthcare executives into ... a 25-bed, not-for-profit critical access hospital and level IV ...
    (Date:12/19/2014)... (PRWEB) December 19, 2014 The ... shifting, capital equipment market that is saturated with ... safety and efficacy as well as non-invasive nature, ... were first introduced to the healthcare market. Rapid ... development of MRI safe technologies have greatly expanded ...
    (Date:12/19/2014)... Hands On Mobile Spa, has announced they now have a ... been transformed into a utopia for the Long Island community ... The Virtual Tour showcases the beauty of the Spa On ... more. , The Virtual Tour shows viewers each of the ... overhauled Winnebago. Marla Kaplan-Pelle, Director states " It's hard to ...
    (Date:12/19/2014)... (PRWEB) December 19, 2014 If you ... having difficulty breathing, you probably wished you had an ... asthma, COPD, cystic fibrosis, and other breathing disorders. Currently, ... medications and avoiding triggers, but other common treatments do ... Educators conference in San Antonio, TX, 34 asthma educators ...
    Breaking Medicine News(10 mins):Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 2Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 3Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 4Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 3Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 2Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 3Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 4Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 2Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 3Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 2Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 3
    ... in Huntingtons disease take place earlier in cell life ... Medicine in Houston in a report that appears in ... research provides evidence of toxicity by huntingtin (the protein ... said Dr. Juan Botas, associate professor of molecular and ...
    ... study finds, , , WEDNESDAY, Jan. 9 (HealthDay News) -- It ... such as schizophrenia and bipolar disorder, very early in the ... five factors that were often present prior to the diagnosis ... high risk of such disorders. When three or more of ...
    ... Time for the Holiday ... ... 50%,of his yearly weight gain during the Holiday Season. That,s not good ... http://www.metabothin.net ), the herbal weight loss formula,from American Generic Laboratories, specifically designed ...
    ... Margolin Named President of Blue Cross of California, ... today announced that Brian A. Sassi has been ... Consumer Business Unit, which,includes the Individual, Senior and ... of Blue Cross of California, replaces Joan,Herman, who ...
    ... on Ice Skating Admission Through ... the End of the Season, PHILADELPHIA, ... and head outdoors this weekend for the,Healthy Kids Fest at the Blue ... for families to enjoy the winter,months, the skating season is in full ...
    ... 9. 2008 -- Two Hebrew University of Jerusalem researchers, ... awarded the 2008 Wolf Prize in Medicine for their ... cancer research. , Minister of Education Prof. Yuli ... the $100,000 prize, often referred to as Israels Nobel ...
    Cached Medicine News:Health News:5 Factors Help Predict Psychosis in Children 2Health News:5 Factors Help Predict Psychosis in Children 3Health News:Metabothin B56 with Ephedra Extract Now Available 2Health News:WellPoint Appoints Brian A. Sassi as President and CEO of the Company's Consumer Business Unit 2Health News:WellPoint Appoints Brian A. Sassi as President and CEO of the Company's Consumer Business Unit 3Health News:Families Encouraged to Enjoy Healthy Kids Fest January 12 at the Blue Cross RiverRink 2Health News:Families Encouraged to Enjoy Healthy Kids Fest January 12 at the Blue Cross RiverRink 3Health News:2 Hebrew University scientists awarded Wolf Prizes 2
    Stainless steel lancet blade in stainless steel....
    In Stainless steel. Available in 1.5, 2.0,3.0 & 3.5 MM...
    AXIOM Multistar is a ceiling-mounted single plane C-Arm system for universal angiography, diagnostics and intervention...
    ... supports the cardiac workflow through Xper: a ... personalized user settings. In addition Xper integrates ... user interface. For example the interventional tools ... controlled from tableside.,The excellent image quality and ...
    Medicine Products: